Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma (Nasdaq: IPHA) will hold a conference call and webcast on May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT to provide a Q1 2026 business update. Management participants include CEO Jonathan Dickinson and CFO Frédéric Lombard.
The live webcast link and telephone registration are on the company website; a replay will be available for 90 days following the event.
Innate Pharma (Nasdaq: IPHA) said its executive team will hold one-on-one investor meetings at the D. Boral Capital Global Conference in New York on May 7, 2026. The meetings are scheduled as part of the conference's investor program and are intended for institutional engagement.
Innate Pharma (Nasdaq: IPHA) will present interim MATISSE Phase 2 results for IPH5201 plus durvalumab and platinum chemotherapy at AACR 2026 on April 21, 2026.
In a pre-planned interim analysis of 40 patients, pathological complete response (pCR) was 35.7% for PD-L1 ≥1% and 50% for PD-L1 ≥50%; enrollment continues in PD-L1 ≥1% patients.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) will hold its Annual General Meeting on May 21, 2026 at 10:30 a.m. CEST at its Marseille headquarters. The notice published April 13, 2026 includes the agenda, proposed resolutions and participation and voting instructions.
Documents and live broadcast will be available on the Investors section of the company's website. A guided laboratory tour for shareholders is scheduled at 9:15 a.m. CEST the same day. Registration, voting eligibility and written question deadlines are specified in the notice.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) reports its share count and voting rights as of April 9, 2026. Total shares outstanding are 93,860,680, comprising 93,847,763 ordinary shares, 5,336 preferred shares 2016, and 7,581 preferred shares 2017.
The total number of theoretical voting rights is 94,484,443 and the total number of exercisable voting rights is 94,465,868. AGAP 2016 instruments carry 130 and 111 voting rights respectively; AGAP 2017 carries no voting rights.
Innate Pharma (Nasdaq: IPHA) announced that COO Yannis Morel will present at the AACR Oncology Industry Partnering Event on April 16, 2026 in San Diego. The presentation is in Showcase Session 2 at 6:10 PM PDT and will highlight the company’s oncology pipeline, including IPH4502.
The session offers direct exposure to investors, analysts and industry partners and may support scientific and business engagement on Innate Pharma’s clinical programs.
Innate Pharma (Nasdaq: IPHA) announced executive team participation in one-on-one investor meetings at the Kempen Life Sciences Conference on April 15–16, 2026 in Amsterdam, Netherlands.
According to the company, meetings will offer direct investor engagement about its clinical-stage immunotherapy programs.
Innate Pharma (Nasdaq: IPHA, Euronext: IPH) filed its 2025 Universal Registration Document with the AMF and its 2025 Form 20-F with the SEC, both filed on April 1, 2026 for the year ended December 31, 2025.
Both documents are available on the company website and respective regulator websites. The Universal Registration Document incorporates the annual financial report, annual management report, corporate governance report under Article L.225-37, and the statutory auditors' report.
Innate Pharma (Nasdaq: IPHA) reported 2025 results and a business update with a cash position of €44.8m as of December 31, 2025 and an anticipated runway to end of Q3 2026. The company plans to initiate the confirmatory TELLOMAK-3 Phase 3 for lacutamab in H2 2026, subject to non-dilutive financing and partnerships.
Key pipeline progress includes preliminary activity for IPH4502, ongoing cohort enrichment, PACIFIC-9 (monalizumab) readout expected H2 2026, MATISSE interim data selected for AACR 2026, and strategic streamlining with workforce reductions.
Innate Pharma (NASDAQ: IPHA) will hold a conference call and webcast on Thursday, March 26, 2026 at 2:00 p.m. CET / 9:00 a.m. EDT following release of full-year 2025 financial results.
Senior management participating includes CEO Jonathan Dickinson and CFO Frédéric Lombard, among others. The live webcast and telephone registration links are available, and a replay will remain on the company website for 90 days.